- BMS works with Exelixis on small-molecule cancer treatments
- BMS and Exelixis collaborate on genetic model systems
- BMS and Exelixis develop anticancer drugs
- BMS licenses Exelixis's LXR program
- GSK, Exelixis co-develop, -promote therapeutics; terminated
- Genentech options rights to Exelixis' XL518; exercised
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.